Perkins, Bruce A.
Lovblom, Leif E.
Bril, Vera
Scarr, Daniel
Ostrovski, Ilia
Orszag, Andrej
Edwards, Katie
Pritchard, Nicola
Russell, Anthony
Dehghani, Cirous
Pacaud, Danièle
Romanchuk, Kenneth
Mah, Jean K.
Jeziorska, Maria
Marshall, Andrew
Shtein, Roni M.
Pop-Busui, Rodica
Lentz, Stephen I.
Boulton, Andrew J. M.
Tavakoli, Mitra
Efron, Nathan
Malik, Rayaz A.
Funding for this research was provided by:
NIH NIDDK (1DP3DK104386-01)
Article History
Received: 10 January 2018
Accepted: 6 April 2018
First Online: 4 June 2018
Duality of interest
: BAP reports grants from CIHR, NIH and JDRF, speaker honoraria from Medtronic, Johnson & Johnson, Insulet, Abbott, Novo Nordisk and Sanofi and research grant support from Medtronic and Boehringer Ingelheim and serves as a consultant for Boehringer Ingelheim, Insulet and Novo Nordisk. NE reports grants from JDRF and NHMRC during the conduct of the study. DP reports grants from NIH RFA DK-13-027 and grants from JDRF during the conduct of the study. JKM has received research grants from Eli Lilly, Pfizer, Bristol-Myers Squibb, PTC Therapeutics, Sanofi Genzyme, Novartis, ReveraGen Pharma and Biogen. SIL reports grants from NIH-DHHS-US through a consortium with Mount Sinai Hospital and grants from NIH-NIDDK Michigan Diabetes Research Center Diabetes Interdisciplinary Study Grant during the conduct of the study. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.